Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Blog

Displaying 1 to 10 of 77 Posts . Displaying 10 of Posts . Page of 8 . Go To Page: . Per Page: . . . View All Sort By: .

Declaración sobre el brote de coronavirus

Declaración del IPC sobre COVID y psoriasis La pandemia de SARS-CoV-2 continúa siendo una preocupación sanitaria de gravedad a nivel global. Desde que el Consejo Internacional de Psoriasis (IPC) publicó su declaración sobre COVID-19 el 11 de marzo, el coronavirus continúa propagándose rápidamente y actualmente constituye un peligro sanitario preponderante en todos los países de ingresos económicos altos, medios y bajos.

Read More

Spanish study identifies 5 skin manifestations in COVID-19 patients

IPC fellow Dr. Romina Contreras talks with Dr. Alba Català about her study on skin manifestations of COVID-19 and how this research contributes to our growing understanding of the novel coronavirus.

Read More

Stories from the field: COVID-19 and dermatology practice in Brazil

Ricardo Romiti, MD, PhD, discusses the COVID-19 situation in Brazil from a derm perspective.

Read More

How to build a registry in record time: an interview with Catherine Smith and Satveer Mahil

The registries, PsoProtect and PsoProtectMe, aim to help health care workers understand how the novel virus affects patients with psoriasis.

Read More

IPC Statement on COVID-19 and Psoriasis

The SARS-CoV-2 pandemic continues to have a considerable impact on the provision of appropriate care to people with psoriasis. In an updated statement, IPC advises physicians and other healthcare practitioners to take into account these important issues that relate to the management of psoriasis during the pandemic.

Read More

Commentary: Psoriasis treat to target: defining outcomes in psoriasis

In moderate to severe psoriasis, there has been a long-lasting tradition to define outcome as a relative change from baseline PASI, with the classical PASI 75 being more recently replaced by PASI 90 or 100. However, this concept is dated, mainly due to the impressive development of anti-interleukin therapies and an increasing interest in real-world evidence.

Read More

COVID-19 y psoriasis: Informes ibero-latinoamericanos

Aprenda más sobre cómo COVID-19 está afectando a las personas con psoriasis. Vea el webinar de IPC para médicos en América Latina con pacientes con psoriasis.

Read More

Commentary: OpenSAFELY: factors associated with COVID-19 death in 17 million patients

Torres writes that several comorbidities known to be associated with psoriasis, such as cardiovascular disease, hypertension, diabetes or obesity, have been identified as risk factors for severe COVID-19 outcomes.

Read More

Classifying Disease Severity

Dr. Strober details the IPC Psoriasis Disease Severity Reclassification project, which advocates for a revised severity scoring system to improve psoriasis patient access.

Read More

WHO Academy COVID-19 mobile app

The WHO Academy’s mobile learning app has been designed specifically for health workers and is now available to download.

Read More
now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

Search Our Blog

  Search
 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK